Lineage Cell Therapeutics, Inc. (LCTX) is a publicly traded Healthcare sector company. As of May 20, 2026, LCTX trades at $1.31 with a market cap of $309.13M and a P/E ratio of -4.38. LCTX moved +8.75% today. Year to date, LCTX is -26.83%; over the trailing twelve months it is +141.25%. Its 52-week range spans $0.37 to $2.09. Analyst consensus is strong buy with an average price target of $6.25. Rallies surfaces LCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns LCTX stock?
Hedge funds tracked by Rallies that own LCTX include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Lineage Cell Therapeutics, Inc..
LCTX Key Metrics
Key financial metrics for LCTX
Metric
Value
Price
$1.31
Market Cap
$309.13M
P/E Ratio
-4.38
EPS
$-0.28
Dividend Yield
0.00%
52-Week High
$2.09
52-Week Low
$0.37
Volume
1.42M
Avg Volume
0
Revenue (TTM)
$14.78M
Net Income
$-64.01M
Gross Margin
0.00%
Top Hedge Funds Holding LCTX
Exoduspoint Capital holds 21.16K shares of LCTX, changed -88.36% as of Mar 31, 2026.
Hedge funds tracked by Rallies that own LCTX include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Lineage Cell Therapeutics, Inc..
Does Rallies show 13F holders for LCTX?
Yes. Rallies tracks hedge fund and 13F ownership data for LCTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is LCTX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LCTX. It does not provide personalized investment advice.
